There is a lot of queasiness around the counter of Sun Pharma as the market is very anxious about the upcoming inspection by the US FDA of its Halol plant. The tentative schedule was second week of Feb which is now.

This Halol unit is the one that had received 9 observations in 2016 for deviations from standard manufacturing quality and procedure norms.

It is very crucial for Sun to come our smelling roses of this inspection, with no observations as this unit is the one that makes a diverse range of medicines.